Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer: Phase III trialSentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer: Phase III trial
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or survival after a median five years of follow-up, according to results from the BOOG 2013-08 Phase III clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Breast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancerBreast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancer
Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional recurrence whether or not they underwent preoperative breast magnetic resonance imaging (MRI) in addition to diagnostic mammography to determine the extent of their cancer, according to results from the Phase III Alliance A011104/ACRIN 6694 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Preoperative radiation may improve antitumor immune response in most common form of breast cancerPreoperative radiation may improve antitumor immune response in most common form of breast cancer
Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of a Phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Sperm donor with hidden cancer gene fathers nearly 200 kids, families blindsidedSperm donor with hidden cancer gene fathers nearly 200 kids, families blindsided
European fertility clinics used cancer-causing sperm for 17 years, prompting urgent calls for genetic screening reforms and international donor limits.
Next-Gen SERD Cuts Breast Cancer Recurrence Risk by 30% in TrialNext-Gen SERD Cuts Breast Cancer Recurrence Risk by 30% in Trial
(MedPage Today) — SAN ANTONIO — In a large phase III trial of adjuvant treatment for early-stage breast cancer, the investigational oral drug giredestrant reduced the risk of invasive disease recurrence by 30% versus standard endocrine therapy…
GLP-1 diabetes drugs linked to lower epilepsy risk in large studyGLP-1 diabetes drugs linked to lower epilepsy risk in large study
A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published in Neurology. A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The Read More
Bone Fractures Down With GLP-1 Drugs in the PictureBone Fractures Down With GLP-1 Drugs in the Picture
(MedPage Today) — Beyond their established cardiometabolic benefits, GLP-1 receptor agonists also may be tied to improved bone health, based on an observational report. Adults with type 2 diabetes on GLP-1 agonists tended to have small but significant… (MedPage Today) — Beyond their established cardiometabolic benefits, GLP-1 receptor agonists also may be tied to Read More
GLP-1 medications show little effect on cancer, study showsGLP-1 medications show little effect on cancer, study shows
A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound, may not lower cancer risk as some had hoped. A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound, may not lower cancer risk as some had hoped.
The potential of GLP-1 drugs to transform medicine exploded in 2025The potential of GLP-1 drugs to transform medicine exploded in 2025
We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the extent of that potential really came to light in 2025 We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight Read More
A multimodal AI model may improve recurrence risk stratification in early breast cancerA multimodal AI model may improve recurrence risk stratification in early breast cancer
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.